N-Glycosylation Regulates the Trafficking and Surface Mobility of GluN3A-Containing NMDA Receptors

Kristyna Skrenkova1,2,3†, Sanghyeon Lee4†, Katarina Lichnerova1,2, Martina Kaniakova2, Hana Hansikova5, Martin Zapotocky6, Young Ho Suh4* and Martin Horak1,2*

1 Department of Cellular Neurophysiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia, 2 Department of Neurochemistry, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czechia, 3 Department of Physiology, Faculty of Science, Charles University in Prague, Prague, Czechia, 4 Department of Biomedical Sciences, Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, South Korea, 5 Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czechia, 6 Department of Computational Neuroscience, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia

OPEN ACCESS

Edited by:
Kimberly Frances Raab-Graham, Wake Forest School of Medicine, United States

Reviewed by:
John J. Woodward, Medical University of South Carolina, United States
Sanjay S. Kumar, Florida State University, United States

*Correspondence:
Martin Horak
martin.horak@iem.cas.cz
Young Ho Suh
suhyho@snu.ac.kr

† These authors have contributed equally to this work.

Received: 14 March 2018
Accepted: 15 May 2018
Published: 04 June 2018

Citation:
Skrenkova K, Lee S, Lichnerova K, Kaniakova M, Hansikova H, Zapotocky M, Suh YH and Horak M (2018) N-Glycosylation Regulates the Trafficking and Surface Mobility of GluN3A-Containing NMDA Receptors. Front. Mol. Neurosci. 11:188. doi: 10.3389/fnmol.2018.00188

N-methyl-D-aspartate receptors (NMDARs) play critical roles in both excitatory neurotransmission and synaptic plasticity. NMDARs containing the nonconventional GluN3A subunit have different functional properties compared to receptors comprised of GluN1/GluN2 subunits. Previous studies showed that GluN1/GluN2 receptors are regulated by N-glycosylation; however, limited information is available regarding the role of N-glycosylation in GluN3A-containing NMDARs. Using a combination of microscopy, biochemistry, and electrophysiology in mammalian cell lines and rat hippocampal neurons, we found that two asparagine residues (N203 and N368) in the GluN1 subunit and three asparagine residues (N145, N264 and N275) in the GluN3A subunit are required for surface delivery of GluN3A-containing NMDARs. Furthermore, deglycosylation and lectin-based analysis revealed that GluN3A subunits contain extensively modified N-glycan structures, including hybrid/complex forms of N-glycans. We also found (either using a panel of inhibitors or by studying human fibroblasts derived from patients with a congenital disorder of glycosylation) that N-glycan remodeling is not required for the surface delivery of GluN3A-containing NMDARs. Finally, we found that the surface mobility of GluN3A-containing NMDARs in hippocampal neurons is increased following incubation with 1-deoxymannojirimycin (DMM, an inhibitor of the formation of the hybrid/complex forms of N-glycans) and decreased in the presence of specific lectins. These findings provide new insight regarding the mechanisms by which neurons can regulate NMDAR trafficking and function.

Keywords: glutamate receptor, glycan, endoplasmic reticulum, excitatory synapse, ion channel, mammalian neuron

Abbreviations: AMPA, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid; BSA, bovine albumin serum; CDG, congenital disorders of glycosylation; COS-7, African Green Monkey kidney fibroblast cell line; DIV, day in vitro; DNJ, 1-deoxynojirimycin; DMM, 1-deoxymannojirimycin; EDTA, ethylenediaminetetraacetic acid; Endo H, endoglycosidase H; ER, endoplasmic reticulum; FBS, fetal bovine serum; GA, Golgi apparatus; GPP, green fluorescent protein 130; GM130, Golgi matrix protein; HEK293, Human Embryonic Kidney 293 cells; HRP, horseradish peroxidase; M, membrane; NMDAR, N-methyl-D-aspartate receptors; PACSIN1, protein kinase C and casein kinase substrate in neurons 1; PFA, paraformaldehyde; PBS, phosphate-buffered saline; PDI, protein disulfide isomerase; PSD-95, postsynaptic density protein 95; PNGase F, peptide-N-glycosidase F; PVDF, polyvinylidene difluoride; P, postnatal day; QD, Quantum dot; SDS, sodium dodecyl sulfate; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SEM, standard error of the mean; TX-100, Triton X-100.
INTRODUCTION

N-methyl-D-aspartate receptors (NMDARs), a subclass of glutamate receptors, are essential for excitatory neurotransmission and synaptic plasticity in the mammalian central nervous system (CNS; Traynelis et al., 2010; Horak et al., 2014). NMDARs are comprised of GluN1 (with eight splice variants), GluN2 (GluN2A through GluN2D), and GluN3 (GluN3A and GluN3B) subunits, all of which have a similar membrane topology. The GluN3A subunit is a recently discovered subunit that co-assembles with GluN1 and GluN2 subunits to form small-conductance GluN1/GluN2/GluN3 receptors; alternatively, GluN3A can co-assemble exclusively with the GluN1 subunit, forming the glycine-activated GluN1/GluN3 receptor (Traynelis et al., 2010; Pachernegg et al., 2012; Kehoe et al., 2013). Several studies showed that the GluN3A subunit is expressed robustly in the rodent brain during early postnatal development; moreover, this subunit plays a role in inhibiting the maturation of excitatory glutamatergic synapses during neural development (Wong et al., 2002; Fiuza et al., 2013; Yuan and Bellone, 2013).

Although many studies have examined the molecular mechanisms that regulate the surface expression and surface mobility of NMDARs, these studies focused largely on NMDAR subtypes containing GluN1/GluN2 subunits (Traynelis et al., 2010; Sanz-Clemente et al., 2012). With respect to posttranslational modifications of GluN3A-containing NMDARs, both tyrosine phosphorylation of the endocytic motif within the C-terminus and interaction between the GluN3A subunit and the endocytic adaptor protein kinase C and casein kinase substrate in neurons 1 (PACSIN1) regulate the surface expression of these NMDARs (Pérez-Otaño et al., 2006; Chowdhury et al., 2013). GluN1/GluN2 receptors have been found to be extensively N-glycosylated in both heterologous expression systems (Chazot et al., 1995; Everts et al., 1997) and native preparations (Huh and Wenthold, 1999; Kaniakova et al., 2016); moreover, we recently reported that two conventional N-glycosylation sites in the GluN1 subunit are required for the release of GluN1/GluN2 receptors from the endoplasmic reticulum (ER; Licherova et al., 2015); however, the role of N-glycosylation in the trafficking and/or surface mobility of NMDARs containing the nonconventional GluN3A subunit has not been examined.

Here, using a combination of microscopy, biochemistry and electrophysiology in mammalian cell lines and primary hippocampal neurons, we examined the role that N-glycosylation plays in the trafficking and mobility of GluN3A-containing NMDARs. We found that two previously identified N-glycosylation sites (N203 and N368) in the GluN1 subunit, as well as three N-glycosylation sites in the N-terminal domain of the GluN3A subunit, are required for surface delivery of GluN3A-containing NMDARs. We also performed deglycosylation and lectin-based analyses of recombinant and endogenous GluN3A subunits, revealing that this subunit contains a wide diversity of N-glycans, including hybrid/complex types. In addition, we found that altering the early steps in the N-glycosylation pathway reduces the surface delivery of GluN3A-containing NMDARs, whereas preventing the subsequent remodeling of N-glycans has no effect. Finally, we found that 1-deoxymannojirimycin (DMM), which inhibits the formation of hybrid/complex forms of N-glycans, increases the surface mobility of GluN3A-containing NMDARs, whereas the lectins conA, WGA, and AAL slow surface mobility. Taken together, these results indicate that N-glycosylation regulates the trafficking and surface mobility of GluN3A-containing NMDARs in mammalian neurons.

MATERIALS AND METHODS

Mammalian Expression Vectors

The untagged GluN1–4a expression vector was obtained from Dr. Robert J. Wenthold (NIDCD, NIH), and the GFP-GluN3A vector was a kind gift from Pérez-Otaño et al. (2001). Point mutations were introduced using the Quick-Change site-directed mutagenesis kit (Agilent Technologies), and the entire GluN-coding region was confirmed by sequencing. The following multiple-site mutant versions of the GluN constructs were generated: GluN1-N61Q-N203Q-N239Q-N276Q-N300Q-N350Q = GluN1–1/2N→Q; GluN1-N368Q-N440Q-N471Q-N491Q-N674Q-N771Q = GluN1–2/2N→Q; GluN1-N61Q-N203Q-N239Q = GluN1–1/4N→Q; GluN1-N276Q-N300Q-N350Q = GluN1–2/4N→Q; GluN1-N368Q-N440Q-N471Q = GluN1–3/4N→Q; GluN1-N440Q-N471Q-N491Q-N674Q-N771Q = GluN1–4/4N→Q; GluN3A-N145Q-N264Q-N275Q-N285Q-N296Q-N300Q-N320Q-N426Q-N439Q-N549Q-N565Q-N886Q = GluN3A–12N→12Q; GluN3A-N145Q-N264Q-N275Q-N285Q-N296Q-N300Q = GluN3A–1/2N→Q; GluN3A-N320Q-N426Q-N439Q-N549Q-N565Q-N886Q = GluN3A–2/2N→Q; GluN3A-N145Q-N264Q-N275Q = GluN3A–1/4N→Q; GluN3A-N285Q-N296Q-N300Q = GluN3A–2/4N→Q; GluN3A-N320Q-N426Q-N439Q-N549Q-N565Q-N886Q = GluN3A–3/4N→Q; GluN3A-N549Q-N565Q-N886Q = GluN3A–4/4N→Q (Supplementary Figures S1, S2).

Mammalian Cell Culture and Transfection

Heterologous African green monkey kidney fibroblast (COS-7) cells and human embryonic kidney 293 (HEK293) cells were cultured in Opti-MEM I media containing 5% (v/v) fetal bovine serum (FBS; Thermo Fisher Scientific). Human fibroblasts were grown in DMEM media (FG0445; Baria) containing 10% FBS (Thermo Fisher Scientific). Human fibroblasts were provided fibroblasts. All cell lines were transfected with DNA vectors using Lipofectamine 2000 (Thermo Fisher Scientific); Kaniakova et al., 2012a). After transfection, the HEK293 cells used for electrophysiology were dissociated using trypsin. The cells used for microscopy and biochemistry were cultured in DMEM media (FG0445; Baria). The untagged GluN1–4a expression vector was obtained from Dr. Robert J. Wenthold (NIDCD, NIH), and the GFP-GluN3A vector was a kind gift from Pérez-Otaño et al. (2001). Point mutations were introduced using the Quick-Change site-directed mutagenesis kit (Agilent Technologies), and the entire GluN-coding region was confirmed by sequencing. The following multiple-site mutant versions of the GluN constructs were generated: GluN1-N61Q-N203Q-N239Q-N276Q-N300Q-N350Q = GluN1–1/2N→Q; GluN1-N368Q-N440Q-N471Q-N491Q-N674Q-N771Q = GluN1–2/2N→Q; GluN1-N61Q-N203Q-N239Q = GluN1–1/4N→Q; GluN1-N276Q-N300Q-N350Q = GluN1–2/4N→Q; GluN1-N368Q-N440Q-N471Q = GluN1–3/4N→Q; GluN1-N440Q-N471Q-N491Q-N674Q-N771Q = GluN1–4/4N→Q; GluN3A-N145Q-N264Q-N275Q-N285Q-N296Q-N300Q = GluN3A–1/2N→Q; GluN3A-N320Q-N426Q-N439Q-N549Q-N565Q-N886Q = GluN3A–2/2N→Q; GluN3A-N145Q-N264Q-N275Q = GluN3A–1/4N→Q; GluN3A-N285Q-N296Q-N300Q = GluN3A–2/4N→Q; GluN3A-N320Q-N426Q-N439Q-N549Q-N565Q-N886Q = GluN3A–3/4N→Q; GluN3A-N549Q-N565Q-N886Q = GluN3A–4/4N→Q (Supplementary Figures S1, S2).
without the trypsinization step. Experiments were performed within 24–48 h of transfection.

**Preparation and Transfection of Primary Hippocampal Neurons**

All animal experiments were conducted in accordance with the guidelines of the European Union directive 2010/63/EU and approved by the Animal Care and Use Committee of the Institute of Physiology of the Czech Academy of Science (CAS). The Institute of Physiology CAS possesses the National Institutes of Health Statement of Compliance with Standards for Humane Care and Use of Laboratory Animals. Primary cultures of hippocampal neurons were prepared from embryonic day 18 Wistar rats (Lichnerova et al., 2015). In brief, the hippocampi were collected in cold Hank's Balanced Salt Solution containing 10 mM HEPES (pH 7.4), and then incubated for 20 min at 37°C in dissection media containing 0.1 mg/ml DNase I and 0.05% trypsin (Merck). The cells were then washed, dissociated by trituration through a fire-polished glass pipette, and resuspended in plating medium consisting of serum-free Neurobasal media with B-27 supplement and L-glutamine and resuspended in plating medium consisting of serum-free Neurobasal media with B-27 supplement and L-glutamine (Thermo Fisher Scientific). The cells were grown at a density of 10^6 cells per cm² on dishes coated with poly-L-lysine (Sigma). The neurons were fed every 2–3 days with plating media and transfected using Lipofectamine 2000.

**Electrophysiology**

Whole-cell patch-clamp recordings of HEK293 cells were performed using an Axopatch 200B amplifier (Molecular Devices). The extracellular recording solution contained (in mM): 160 NaCl, 2.5 KCl, 10 HEPES, 10 glucose, 0.2 ethylenediaminetetraacetic acid (EDTA), and 0.7 CaCl₂ (pH adjusted to 7.3 with NaOH). The internal pipette solution contained (in mM): 125 gluconic acid, 15 CsCl, 5 BAPTA, 10 HEPES, 3 MgCl₂, 0.5 CaCl₂, and 2 ATP-Mg salt (pH adjusted to 7.2 with CsOH). Glass patch pipettes (3–6 MΩ resistance when filled with internal solution) were prepared using a model P-97 micropipette puller (Sutter Instrument Co.). A microprocessor-controlled multi-barrel rapid perfusion system with a time constant for solution exchange around the cell of 10–20 ms was used to apply a solution containing glycine (Kaniakova et al., 2016). All electrophysiology experiments were performed at room temperature.

**Immunofluorescence Microscopy**

Surface NMDARs were labeled as described previously (Kaniakova et al., 2012a; Lichnerova et al., 2015). In brief, the cells were washed in phosphate-buffered saline (PBS), and then incubated in blocking solution containing PBS and 10% (v/v) normal goat serum. The cells were then incubated for 30 min with the primary antibody diluted in blocking solution. After washing, the cells were incubated for 30 min with a secondary antibody conjugated with a fluorescent dye and diluted in blocking solution. Surface NMDARs were labeled as described previously (Kaniakova et al., 2016). All electrophysiology experiments were performed at room temperature.

Intracellular GluN3A subunits were detected using the InsightSSI illumination module, an oil immersion objective (60×1.42, PlanApo N), and a QD605-conjugated anti-rabbit IgG and then fixed with 4% PFA in PBS as described above. QD movements were analyzed on whole-cell cultures of hippocampal neurons and fibroblasts were analyzed on whole-cell areas (Kaniakova et al., 2012b). For hippocampal neurons, the intensity of the surface and total GFP signals in the COS-7 cells and fibroblasts were analyzed on whole-cell areas (Kaniakova et al., 2012b). For hippocampal neurons, the intensity of the surface and total GFP signals was analyzed in 10-µm long segments of secondary and tertiary dendrites (Lichnerova et al., 2015). The spine/dendrite fluorescence intensity ratio was measured across the dendrite and spine and analyzed using a line plot. The maximum fluorescence intensity of each dendrite and adjacent spine was used to calculate the spine/dendrite ratio as described previously (Gerges et al., 2004). Rhodamine-labeled conA and PHA-L (Vector Laboratories; 20 µg/ml) were dissolved in blocking solution and incubated for 5 min with pre-washed live cells. For nuclear staining, Hoechst 33,342 (Thermo Fisher Scientific; 5 µM) was incubated with the live cells for 30 min. The cells were then washed, fixed in 4% PFA in PBS for 20 min, and mounted using ProLong Antifade reagent.
the short-range diffusion coefficient, D, was obtained from the linear fit of the first four points of the computed mean-squared displacement (MSD) vs. time delay t as follows: \( \text{MSD}_t = 4 D t + b \) (Kusumi et al., 1993; Triller and Choquet, 2008). Out of the total 1254 analyzed trajectories, 10 trajectories gave a negative slope in the MSD linear fit. These 10 trajectories were assigned the diffusion coefficient \( D = 0 \). The cumulative probability distributions were computed as the relative cumulative frequency of D from all trajectories in the indicated experiment.

Deglycosylation and Lectin-Based Biochemical Assays
Deglycosylation experiments were performed using rat cultured hippocampal neurons solubilized for 30 min at 37°C in 1% (w/v) sodium deoxycholate in 50 mM Tris-HCl containing 1 mM EDTA and protease inhibitors (Roche; pH 7.3), followed by centrifugation at 30,000 \( g \) for 30 min at 4°C. The hippocampal lysates were then denatured in Denaturing Buffer (New England Biolabs) at 100°C for 10 min in accordance with the manufacturer’s protocol. Transfected HEK293 cells were directly collected in Denaturing Buffer. For peptide-N-glycosidase F (PNGase F) treatment, 10\( \times \) G7 reaction buffer, 10% (v/v) Nonidet P-40, and 500 units of PNGase F were added. For endoglycosidase H (Endo H) treatment, 10\( \times \) G5 reaction buffer and 1000 units of Endo H were added. Experiments using O-glycosidase and neuraminidase (both from New England Biolabs) were formed in accordance with the manufacturer’s protocol. The samples were incubated at 37°C either for 2 h or overnight, then heated for 3 min at 80°C in 2\( \times \) sodium dodecyl sulfate (SDS) loading buffer.

For the lectin association experiments, 800 \( \mu \)g of total protein lysates from rat cultured hippocampal neurons or transfected HEK293 cells (prepared as described above) was incubated with biotinylated/agarose-linked lectin (40 \( \mu \)l; Vector Laboratories) with rotation at 4°C overnight. The samples containing biotinylated lectins were then incubated with 40 \( \mu \)l of streptavidin-coated agarose beads (Vector Laboratories) for 2 h at room temperature. The samples were washed three times with wash buffer containing 0.1% (w/v) TX-100 in Tris-buffered saline (pH 7.4), and then heated for 3 min at 80°C in 2\( \times \) SDS loading buffer (25 \( \mu \)l). The proteins were separated by electrophoresis in a 5% or 7% SDS-polyacrylamide gel (SDS-PAGE), transferred to a polyvinylidene difluoride (PVDF) membrane, then incubated with the respective primary and secondary antibodies. The signal was detected using enhanced chemiluminescence with BioMax MR X-ray film (Eastman Kodak). The intensity of the protein bands was quantified using ImageJ software and normalized to the values obtained from the respective negative control.

Drugs, Enzymes, Lectins and Antibodies
The following inhibitors of N-glycosylation were used in this study: tunicamycin (Tocris), 1-deoxynojirimycin (DN; Merck), kifunensine (Merck), DMM (Tocris), and swainsonine (Tocris); the final concentration of DMSO in the culture media was <0.1%. PNGase F (10,000 U/ml) was applied to live HEK293 cells in PBS containing 1 mM MgCl\(_2\) and 0.1 mM CaCl\(_2\) at 37°C as described previously (Lichnerova et al., 2015). Unconjugated conA, WGA and AAL (Vector Laboratories), which were used in QD tracking experiments, were dissolved in accordance with the manufacturer’s recommendations; the stock solutions were diluted to a final concentration of 20 \( \mu \)g/ml in extracellular recording solution prior to imaging. The following primary antibodies were used for biochemistry: rabbit anti-GluN3A (1:1000; Merck), anti-GFP (1:1000; Merck), and anti-GluN1 (clone 54.2; 1:1000; from Dr. Wenthold, NIDCD/NIH); the following secondary antibodies were used: horseradish peroxidase (HRP)—conjugated donkey anti-rabbit and donkey anti-mouse (1:1000; Amersham). The following primary antibodies were used for fluorescence microscopy: rabbit anti-GFP (1:1000; Merck), mouse anti-GFP (1:500, Abcam), mouse anti-protein disulfide isomerase (PDI) (1:200; Abcam), rabbit anti-Golgi matrix protein 130 (GM130) (1:500; Merck), and mouse anti-postsynaptic density protein 95 (PSD-95) (1:500; Merck); the following secondary antibodies were used: Alexa Fluor 488/647-conjugated goat anti-mouse and goat anti-rabbit (1:1000; Thermo Fisher Scientific).

Statistical Analysis
Group differences were analyzed using the unpaired Student’s t-test or one-way ANOVA followed by the Student-Newman-Keuls test, where indicated in the figure legends. The distributions of diffusion coefficients were compared using the Mann-Whitney-Wilcoxon test and the Kolmogorov-Smirnov test.

RESULTS
N-Glycosylation at Specific Sites Regulates the Surface Delivery of GluN3A-Containing NMDARs in Mammalian Cell Lines and Hippocampal Neurons
We previously reported that two N-glycosylation sites in the GluN1 subunit (specifically, N203 and N368) regulate the release of GluN1/GluN2 receptors from the ER (Figure 1A; Lichnerova et al., 2015). Here, we first examined whether specific N-glycosylation site(s) in GluN1 and/or GluN3A are required for the trafficking of GluN3A-containing NMDARs to the cell surface. Our electrophysiological measurements in transfected HEK293 cells showed that co-expressing the GluN1–4a splice variant with GluN3A produces larger glycine-induced currents compared to co-expressing the GluN1–1a subunit (data not shown); this finding is consistent with previous reports (Smothers and Woodward, 2009; Cummings and Popescu, 2016). Therefore, we generated mutant versions of the GluN1–4a subunit (hereafter referred to as GluN1) in which various combinations of the 12 consensus N-glycosylation sites were replaced with a glutamine residue (N→Q). We then expressed these subunits in COS-7 cells and measured both total and surface expression. We found that replacing the first six N-glycosylation sites (i.e., 1–6; GluN1–1/2N→Q) or the second six sites (i.e., 7–12; GluN1–2/3N→Q) significantly reduced the surface delivery of the resulting GluN1/GluN3A...
NMDARs (Figures 1B,C). Interestingly, mutating various triplet sets of N-glycosylation sites in GluN1–4a either had no effect on surface delivery (GluN1–2/4N→Q and GluN1–4/4N→Q) or significantly reduced the surface delivery (GluN1–1/4N→Q and GluN1–3/4N→Q) of the resulting GluN1/GluN3A receptors (Figures 1B,C). This suggests that specific N-glycosylation sites in the GluN1–4a subunit regulate the delivery of GluN1/GluN3A receptors to the cell surface. Next, we mutated each of the six N-glycosylation sites in the GluN1–1/4N→Q and GluN1–3/4N→Q subunits and expressed each construct together with the GluN3A subunit in COS-7 cells. These experiments revealed that N-glycosylation at both N203Q and N368Q is essential for receptor trafficking to the cell surface; mutating either of these two sites significantly reduced surface expression of GluN1/GluN3A NMDARs (Figure 1C). Thus, these two specific N-glycosylation sites in the GluN1 subunit regulate the surface delivery of both GluN1/GluN2 NMDARs and GluN1/GluN3A NMDARs.

Similar to the GluN1 subunit, the GluN3A subunit also contains 12 consensus N-glycosylation sites (Figure 1D). We therefore systematically mutated the 12 sites in GluN3A using a strategy similar to the GluN1–4a subunit and measured total and surface expression of the resulting GluN1/GluN3A receptors expressed in COS-7 cells (Figures 1E,F). We found that replacing all 12 N-glycosylation sites in the GluN3A subunit (GluN3A-12N→Q) virtually eliminated the surface expression of GluN1/GluN3A receptors. Furthermore, mutating the first six sites (GluN3A-1/2N→Q), but not the second six sites (GluN3A-2/2N→Q), also reduced the surface expression of GluN1/GluN3A receptors. Interestingly, similar to our screen of the GluN1–4a subunit, mutating various triplet N-glycosylation sites in the GluN3A subunit either had no effect (GluN3A-2/4N→Q, GluN3A-3/4N→Q, and GluN3A-4/4N→Q) or significantly reduced the surface delivery (GluN3A-1/4N→Q) of GluN1/GluN3A receptors (Figures 1E,F). Lastly, we mutated each of the 12 N-glycosylation sites in the GluN3A subunit and co-expressed each mutant together with GluN1–4a in COS-7 cells. These experiments revealed that no single N-glycosylation site in GluN3A is essential for the surface delivery of GluN1/GluN3A receptors (Figures 1E,F). Together, our experiments showed that simultaneous glycosylation of all three key asparagine residues—N145, N264, and N275—in the GluN3A subunit is required for surface delivery of GluN1/GluN3A receptors in cultured mammalian cells; this conclusion is supported by a biotinylation assay in transfected HEK293 cells (Figures 2A,B).

To confirm that these three asparagine residues in the GluN3A subunit are indeed occupied by N-glycans, we co-expressed the mutant GluN3A subunits together with the GluN1 subunit in HEK293 cells and analyzed the proteins using a gel-shift assay (Figures 2C,D). Interestingly, the gel mobility of the GluN3A-12N→12Q subunit (with all 12 N-glycosylation sites mutated) was similar to the wild-type GluN3A subunit treated with PNGase F, which removes all types of N-glycans, from glycoproteins, indicating that many of the 12 conventional N-glycosylation sites in GluN3A are indeed glycosylated. We also examined other mutant GluN3A subunits and found that gel mobility was shifted (relative to wild-type) for GluN3A subunits lacking either six (GluN3A-1/2N→Q; GluN3A-2/2N→Q) or three (GluN3A-1/4N→Q) N-glycosylation sites (Figure 2C). Lastly, we examined the effect of mutating each of the three sites identified as essential for surface delivery and found that all three single mutant subunits (i.e., N145Q, N264Q and N275Q) had altered gel mobility relative to the wild-type GluN3A subunit; in addition, the GluN3A-12N→12Q, GluN3A-1/2N→Q and GluN3A-1/4N→Q mutants had altered mobility as well (Figure 2D). Taken together, these results confirm that three specific asparagine residues (N145, N264, and N275) in the GluN3A subunit are indeed N-glycosylated when expressed in HEK293 cells.

To examine the functional relevance of these N-glycosylation sites in GluN subunits, we examined whether GluN1–4a...
and/or GluN3A subunits lacking specific N-glycosylation sites can form functional channels at the cell surface. We therefore co-transfected HEK293 cells with wild-type or mutant GluN1–4a subunits together with wild-type or mutant GluN3A subunits and recorded whole-cell currents induced by rapid application of 500 μM glycine (Figures 2E,F). We observed robust glycine-induced currents in the majority of the GluN1–4a/GluN3A subunit combinations examined, whereas no detectable currents were measured when cells expressed GluN1–1/2N→Q/GluN3A, GluN1–2/2N→Q/GluN3A, GluN1–1/4N→Q/GluN3A, or GluN1–3/4N→Q/GluN3A receptors (Figures 2E,F). These findings are consistent with our microscopy and biochemistry data, confirming that these specific NMDARs are not delivered to the cell surface. Our analysis of the currents mediated by wild-type GluN1/GluN3A receptors showed a weighted time constant for desensitization (τw of desensitization) of approximately 55 ms, consistent with previous studies regarding this receptor subtype (Cummings and Popescu, 2016); moreover, similar τw values were measured in the subunit combinations that yielded detectable currents (Figures 2E,F). Indeed, the co-application of a competitive antagonist 5,7-dichlorokynurenic acid (5,7-DCKA; 10 μM or 100 μM) resulted in complete inhibition of the GluN1/GluN3A receptor-mediated currents.
inhibition of the GluN1/GluN3A receptor-mediated currents (Figure 2G). Thus, our electrophysiological experiments indicate that the removal of most of the N-glycosylation sites, including the GluN3A-1/4N→Q mutant, did not affect the ability to form functional GluN1/GluN3A receptors at the cell surface. This conclusion is supported by our analysis of HEK293 cells incubated with a high concentration of PNGase F, which targets N-glycans at the cell surface (but does not affect delivery of the subunit to the cell surface); treating cells that express wild-type GluN1/GluN3A receptors with PNGase F did not significantly affect the τw of desensitization (Figure 2F).

Next, we expressed wild-type or mutant forms of GluN3A in cultured hippocampal neurons and measured their surface expression. Consistent with our results obtained with COS-7 cells, neurons that express the GluN3A-12N→12Q, GluN3A-1/2N→Q, or GluN3A-1/4N→Q subunits—but not cell that express GluN3A-2/2N→Q subunits—have reduced surface expression relative to wild-type GluN3A subunits (Figures 3A,B). We then performed co-immunofluorescence experiments in hippocampal neurons expressing either wild-type or mutant GluN3A subunits, using antibodies against PSD-95 (an excitatory synapse marker), PDI (an ER marker), or GM130 (a Golgi apparatus (GA) marker). To measure the delivery of GluN1 subunits to a greater extent than the wild-type GluN3A subunits in these neurons (Prybylowski et al., 2002).

These experiments revealed that recombinant GluN1 and GluN3A subunits co-expressed in HEK293 cells have similar electrophoretic mobility regardless of whether the cells were treated with PNGase F or Endo H (Figure 4A). Similarly, the electrophoretic mobility of Endo H-treated endogenous GluN1 subunits was similar to the electrophoretic mobility of PNGase F-treated endogenous GluN1 subunits, consistent with previous reports (Huh and Wenthold, 1999). In contrast, Endo H treatment had a different effect on the electrophoretic mobility of endogenous GluN3A subunits compared to PNGase F treatment, indicating that the N-glycans present on endogenous GluN3A subunits are complex N-glycans. Interestingly, a small fraction of GluN3A subunits was completely insensitive to both PNGase F and Endo H treatment, showing no change in electrophoretic mobility even after the cells were treated for >24 h (data not shown); this fraction of GluN3A subunits was also unaffected by both neuraminidase and O-glycosidase treatment (Figure 4B), suggesting that this resistant fraction of GluN3A subunits is neither N-glycosylated nor O-glycosylated.

Next, we asked which N-glycan structures are incorporated into recombinant and endogenous GluN3A subunits using a comprehensive panel of conjugated lectins. Detailed information regarding the glycan specificities of the lectins tested is provided in Table 1. After precipitating specific lectin-bound proteins from lysates prepared from HEK293 cells and cultured hippocampal neurons, we measured the relative levels of the GluN3A subunit using western blot analysis (Figures 4C,D). Interestingly, the GluN3A subunits in both cell types were strongly pulled down with lectins that recognize high-mannose, hybrid, and complex N-glycans, including conA, WGA, AAL, PSA, LCA, DSL and SNA. These differences observed in lectin sensitivity (e.g., RCA, PHA-E, ECL and LEL) between HEK293 cells and hippocampal neurons likely reflect differences in the N-glycosylation machinery between these two cell types. Taken together, these data indicate that both recombinant and endogenous GluN3A subunits contain a broad diversity of N-glycan structures, including hybrid and/or complex forms.

**N-Glycan Remodeling Is Not Required for Surface Delivery of GluN3A-Containing NMDARs**

Next, we asked whether remodeling of N-glycans affects the trafficking of GluN3A-containing NMDARs to the cell surface. First, we expressed recombinant GluN1 subunits in human fibroblast cell lines derived from patients with various congenital disorders of glycosylation (CDG; see Table 2), as well as control cells, and measured the surface expression...
of GluN1/GluN3A receptors (Figure 5A). These experiments revealed that control fibroblasts and four of the five CDG fibroblast lines have robust surface delivery of GluN1/GluN3A receptors (Figures 5A,B; Table 2). In contrast, the ALG8-CDG line, which has reduced formation of N-glycans in the ER, had significantly reduced surface delivery of GluN1/GluN3A receptors. Thus, reduced N-glycosylation within the ER—but not altered N-glycan remodeling—reduces the delivery of GluN1/GluN3A receptors to the cell surface.

Next, we asked whether inhibiting the N-glycosylation machinery affects the surface delivery of GluN3A-containing NMDARs. We first incubated COS-7 cells for 2 days in the presence or absence of various inhibitors, including 1 µg/ml tunicamycin (an inhibitor of dolichyl-phosphate N-acetylglucosamine phosphotransferase I; Yavin et al., 1984), 200 µg/ml DNJ (an inhibitor of α-glucosidase I-II; Gross et al., 1986), 5 µg/ml kifunensine (an inhibitor of the ER α-mannosidase I; Herreman et al., 2003), 200 µg/ml DMM (an inhibitor of the ER α-mannosidase I-II; Tokhtaeva et al., 2009), or 100 µg/ml swainsonine (an inhibitor of the GA α-mannosidase II; Liu et al., 2000). With the exception of DNJ, the other four inhibitors drastically reduced surface labeling.
with fluorescently tagged PHA-L (which recognizes complex types of N-glycans; Figure 5C). In contrast, with the exception of tunicamycin, the other four inhibitors increased surface labeling with fluorescently tagged conA (which recognizes the high-mannose forms of N-glycans; Figure 5C). These results indicate that treating COS-7 cells with tunicamycin, kifunensine, DMM, and swainsonine inhibits the N-glycosylation machinery.

Using these inhibitors in transfected COS-7 cells, we found reduced surface delivery of GluN1/GluN3A receptors in cells treated with tunicamycin; in contrast, DNJ, kifunensine, DMM, and swainsonine had no effect on the surface delivery of GluN1/GluN3A receptors (Figures 5D,E). These data support our hypothesis that the initial attachment of N-glycans in the ER—but not the subsequent remodeling of N-glycan composition—is required for surface delivery of GluN1/GluN3A receptors. Next, we cultured hippocampal neurons for 2 days with 0.5 µg/ml tunicamycin (this slightly reduced concentration was used because 1 µg/ml was toxic to these neurons; data not shown) or the same concentrations of DNJ, kifunensine, DMM, and swainsonine listed above. These experiments revealed a pattern of labeling with fluorescently tagged conA and PHA-L that was similar to our results obtained with COS-7 cells (Figure 6A), confirming that four of the five inhibitors effectively impaired the N-glycosylation machinery. Finally, we found that tunicamycin—but not DNJ, kifunensine, DMM, or swainsonine—drastically reduced the surface delivery of the recombinant GFP-GluN3A subunit in hippocampal neurons (Figures 6B,C). Similar results were obtained with respect to the surface delivery of endogenous GluN3A subunits measured in hippocampal neurons treated with these five inhibitors (Figures 6D,E). Taken together, these data indicate that remodeling of N-glycans does not play an essential role in the surface delivery of GluN3A-containing NMDARs.

**The Lateral Mobility of GluN3A Subunits at the Cell Surface In Hippocampal Neurons Is Bi-directionally Regulated By N-Glycosylation**

Lastly, we investigated the role of N-glycosylation in regulating the lateral mobility of GluN3A-containing NMDARs at the surface of hippocampal neurons. First, we treated hippocampal neurons with the N-glycosylation inhibitors DMM and...
**TABLE 1** | Glycospecificities of the lectins used for the immunoprecipitation experiments.

| Shortcut | Lectin | Preferred glycan specificity<sup>1</sup> |
|---------|--------|-----------------------------------|
| ConA    | Concanavalin A | αMan, GlcNAc |
| WGA     | Wheat germ agglutinin | Fucα1,GlCNAc |
| AAL     | Aleuria aurantia | αGalNAc, Galβ1GalNAc |
| DBA     | Dolichos biflorus | αβGalNAc |
| PNA     | Peanut | αFuc |
| SBA     | Soybean | Gal |
| UEIA    | Ulex europaeus | αGalα/GalNAc |
| RCA     | Ricinus communis | Gal |
| GSL I   | Griffonia simplicifolia I | Galα/GalNAc |
| PSA     | Pisum sativum | αMan, αMan |
| LCA     | Lens culinaris | αMan |
| PHA-E   | Phaseolus vulgaris Erythraeagglutinin | αGalβ1GalNAc, Manα2Galβ1Manα2, Manβ4 |
| PHA-L   | Phaseolus vulgaris Leucoagglutinin | αGalβ1GalNAc, GlcNAcβ1GalNAcβ4, GlcNAcβ1Manα2Galβ1Manα2, Manβ3 |
| SJA     | Sophora japonica | αβGalNAc |
| STWGA   | Succinylated wheat germ agglutinin | GlcNAc |
| GSL II  | Griffonia simplicifolia II | αβGlcNAcN |
| DSL     | Datura stramonium | αβGlcNAcN, βGlcNAcN, βGlcNAcN, βGlcNAcN |
| ECL     | Erythrina cristagalli | Galβ1GlcNAcN |
| Jacalin | Jacalin | Galβ3GalNAc |
| LEL     | Lycopersicon esculentum | αβGlcNAcN, βGlcNAcN |
| STL     | Solanum tuberosum | βGlcNAcN, βGlcNAcN |
| VVA     | Vicia villosa | αβGalNAc |
| SNA     | Sambucus nigra | Neuα2Acα2Gal/GalNAc |

Adapted from the Vector Laboratories manual and from Varki et al. (2009). See Figure 4 for further details. <sup>1</sup>Man, mannos; GlcNAc, N-acetylglucosamine; Gal, galactose; GalNAc, N-acetylgalactosamine; Fuc, fucose; Neu5Ac, N-acetylneuraminic acid.

**DISCUSSION**

Here, we present compelling evidence that N-glycosylation of the GluN3A NMDAR subunit is required for the receptor’s delivery to the cell surface, based on results obtained using both heterologous expression systems and cultured neurons. The precise mechanism by which this process is mediated is currently unknown. One possibility is that the presence of specific N-glycans confers a critical structural GluN3A-containing NMDARs, thereby permitting their release from the ER (Vagin et al., 2009). Another possibility is that the GluN subunits interact with specific glycan-binding proteins such as galactose-binding lectins (Copits et al., 2014), which then facilitates the trafficking of GluN3A-containing NMDARs to the cell surface. Interestingly, our results indicate that trafficking of GluN1/GluN3A receptors is more dependent upon N-glycosylation of the GluN1 subunit than upon N-glycosylation of the GluN3A subunit. This conclusion is supported by our recent findings with respect to GluN1/GluN2 receptors (Lichnerova et al., 2015).
FIGURE 5 | Remodeling of N-glycans is not essential for surface delivery of recombinant GluN1/GluN3A receptors. (A) The indicated human fibroblasts were transfected with GluN1 and GluN3A. Detailed information regarding the fibroblasts used here is provided in Table 2. Representative images of total and surface pools of labeled subunits 24 h after transfection are shown. (B) Summary of the normalized surface expression of GluN1/GluN3A receptors measured using fluorescence microscopy; \( n \geq 20 \) cells from two independent experiments. \( \ast p < 0.05 \) vs. the GluN1/GluN3A signal in the control group (ANOVA). (C) COS-7 cells were treated for 2 days with 1 \( \mu \)g/ml tunicamycin, 200 \( \mu \)g/ml 1-deoxynojirimycin (DNJ), 5 \( \mu \)g/ml kifunensine, 200 \( \mu \)g/ml 1-deoxymannojirimycin (DMM), or 100 \( \mu \)g/ml swainsonine. The cells were then labeled with fluorescently tagged conA or PHA-L and Hoechst 33342 (Hoechst); representative images are shown. (D) COS-7 cells were transfected with GluN1 and GluN3A and then treated with the N-glycosylation inhibitors as described above. Representative images of total and surface pools of labeled GluN1/GluN3A receptors are shown. (E) Summary of the normalized surface expression of GluN1/GluN3A receptors measured using fluorescence microscopy; \( n \geq 30 \) cells. \( \ast p < 0.05 \) vs. the control group (ANOVA).

Our biochemical analyses revealed that the GluN3A subunit is extensively N-glycosylated, similar to both the GluN1 and GluN2 subunits (Clark et al., 1998; Huh and Wenthold, 1999; Kenny et al., 2009; Qiu et al., 2009; Kaniakova et al., 2012b; Lichnerova et al., 2015; Hanus et al., 2016). We found that the GluN3A subunit in rat hippocampal neurons contains a rich diversity of N-glycans, including hybrid and/or complex forms, which suggests that its N-glycan composition undergoes remodeling in the GA. In principle, the N-glycan composition of GluN3A-containing NMDARs could be modified in the somatic GA, dendritic Golgi outposts, and/or Golgi satellite structures (Mikhaylova et al., 2016). Indeed, N-glycosylation machinery is present in the dendrites of hippocampal neurons (Torre and Steward, 1996; Mikhaylova et al., 2016); thus, it is reasonable to speculate that all cellular Golgi systems play a role in the N-glycan processing of GluN3A-containing NMDARs. Other ionotropic glutamatergic receptors, including 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid (AMPA) receptors and kainate receptors, also contain a variety of N-glycan forms (Standley et al., 1998; Greger et al., 2003; Mah et al., 2005; Coleman et al., 2006; Hanus et al., 2016); thus, it is likely that the N-glycan composition of all ionotropic glutamate receptors regulates their trafficking and function in vivo.

Our analysis revealed differences in the sensitivity of GluN3A subunits expressed in hippocampal neurons vs. HEK293 cells to Endo H and several lectins. A likely explanation for this may be explained by differences in the N-glycosylation machinery between these two cell types, similarly as was shown previously for many glycoproteins in various mammalian cell types (Croset et al., 2012; Medzihradzky et al., 2015). Indeed, these findings suggest that caution should be used when selecting an experimental model for functional studies.
N-Glycosylation of GluN3A-Containing NMDARs

Using NMDARs. On the other hand, we observed a similar pattern between hippocampal neurons and cell lines with respect to the surface expression of mutant GluN3A subunits that lack specific N-glycosylation sites. Similarly, we found that only tunicamycin—which inhibits the initial step in the N-glycosylation process—reduced the surface expression of GluN3A-containing NMDARs; this effect was similar between hippocampal neurons and cell lines. We also studied human fibroblasts obtained from patients with deficits in N-glycosylation machinery and found reduced surface delivery of GluN1/GluN3A receptors only in cells in which the initial step in the N-glycosylation pathway is impaired (i.e., ALG8-CDG). Taken together, our data suggest that the trafficking machinery in heterologous expression systems and cultured hippocampal neurons uses a common quality-control mechanism to regulate the trafficking of GluN3A-containing NMDARs.

Our finding that N-glycan remodeling is not required for the surface delivery of GluN3A-containing NMDARs is consistent with a recent study by Hanus et al., who reached a similar conclusion with respect to various neuronal membrane proteins (Hanus et al., 2016). In addition, we found that the mobility of QD-labeled GluN3A subunits at the surface of hippocampal

FIGURE 6 | Tunicamycin, but not inhibitors of later step in the N-glycosylation pathway, reduces the surface delivery of GluN3A subunits in hippocampal neurons. (A) Hippocampal neurons were treated for 2 days with 0.5 \( \mu \text{g/ml} \) tunicamycin, 200 \( \mu \text{g/ml} \) DNJ, 5 \( \mu \text{g/ml} \) kifunensine, 200 \( \mu \text{g/ml} \) DMM, or 100 \( \mu \text{g/ml} \) swainsonine. The neurons were then labeled with fluorescently tagged conA or PHA-L and Hoechst 33342 (Hoechst); representative examples are shown. (B) Hippocampal neurons were transfected with GFP-GluN3A (GluN3A) at DIV8 and treated for 2 days with the indicated inhibitors as described above. The neurons were then immunostained for total and surface GFP under non-permeabilizing and permeabilizing conditions, respectively; representative images of total and surface immunoreactivity are shown. (C) Summary of the relative surface expression of GluN3A subunits in neurons treated with the indicated inhibitors; data were obtained from 10-\( \mu \text{m} \) long segments of secondary and tertiary dendrites (\( n \geq 30 \) segments from \( \geq 6 \) neurons) and are expressed relative to control-treated neurons; \( ^{\star}p < 0.05 \) vs. control (ANOVA). (D) A surface biotinylation assay was performed at DIV15 on dense cultures of hippocampal neurons treated for 2 days with the indicated inhibitors applied at the concentrations described above. (E) Graph of the relative surface expression measured using the surface biotinylation assay shown in (D); the intensity of the surface and total GluN3A bands were quantified using ImageJ; the black dots indicate the values obtained in the individual experiments; \( n = 4 \). \( ^{\star}p < 0.05 \) vs. control (Student’s t-test).
neurons increases when hybrid and complex forms of N-glycans are removed. These findings are consistent with the report that the mobility of AMPARs can be regulated by enzymatic removal of the extracellular matrix (Frischknecht et al., 2009). In contrast, the diffusion coefficient of GluN3A subunits was reduced in the presence of lectins compared to control cells, corresponding to an approximately 4-fold increase in the time required to diffuse across a given short distance. Indeed, one possible interpretation of our data is that the lectins used in our study may indirectly affect the mobility of GluN3A-containing NMDARs by interacting with other glycoproteins at the neuronal cell surface. Because a wide variety of lectins are expressed in the mammalian CNS, including sialic acid-binding Ig-like lectins (Macauley et al., 2014) and galactose-binding lectins (Cummings et al., 2017), these lectins could affect the mobility of NMDARs in vivo. Other groups reported similar findings; for example, the binding of conA restricts the mobility of surface receptors for this lectin in mouse fibroblasts (Zagyansky and Edidin, 1976), and the protein galectin-3 alters the lateral mobility and clustering of β1-integrin receptors in HeLa cells (Yang et al., 2017).

The GluN3A subunit acts as a molecular brake, limiting the maturation of excitatory synapses; this subunit has also been implicated in a number of neuropsychiatric disorders (Fiuza et al., 2013; Kelhoe et al., 2013, 2014). Thus, N-glycosylation may play as-yet unrecognized roles in the mammalian brain during health and/or disease. For example, N-glycosylation of the GluN3A subunit may be essential for its synaptic/perisynaptic localization and/or degradation (Pachernegg et al., 2012; Chowdhury et al., 2013). With respect to the clinical relevance of our findings, it is interesting to note that the glycosylation pattern on AMPARs is altered in the cerebral cortex of schizophrenia patients (Tucholski et al., 2013); therefore, it is reasonable to speculate that the N-glycosylation pattern of the GluN3A subunit may be altered in certain neurological and/or psychiatric conditions. Here we used lines with PMM2-CDG and PGM1-CDG which have defects in glycan precursor biosynthesis in cytosol, SRD5A3-CDG and DPAGT1-CDG with defect in the first steps of lipid-linked oligosaccharide synthesis (dolichol biosynthesis and cycle) on cytosolic side of ER and ALG8-CDG with defect in extension of oligosaccharide chain inside ER (references shown in Table 2). All of these defects are accompanied with neurological impairments (Freeze et al., 2015). Concerning the ALG8 deficiency (OMIM #608104), it is known that most of ALG8-deficient patients died within the first months of life. These cases were accompanied by multiple symptoms such as strong dysmorphic features, hypotonia, gastrointestinal disorders, hepatomegaly, coagulopathy, edema, cardiorespiratory problems, protein-losing enteropathy and ascites (Haupertle and Hennet, 2009). Neurological dysfunctions included psychomotor disability, seizures, ataxia and structural abnormalities (dilatation of ventricles, corpus callosum hypoplasia, leukoencephalopathy/leukodystrophy and cortical/cerebral atrophy (Höck et al., 2015). We used fibroblast line derived from patient with mutations c.139A>C (p.T47P) and

---

**FIGURE 7** N-glycosylation regulates the mobility of GluN3A-containing NMDARs at the cell surface of hippocampal neurons. (A,C) Representative trajectories of quantum dot (QD)-labeled GFP-GluN3A (GluN3A) subunits in hippocampal neurons treated with 200 µg/ml DMM (A) or with the lectin AAL (20 µg/ml) (C). (B,D) Comparison of the cumulative distribution of the diffusion coefficients measured for QD-labeled GluN3A subunits in hippocampal neurons treated for two days with 200 µg/ml DMM, 100 µg/ml swainsonine (n = 208–314 trajectories per condition; B), or incubated after QD labeling with 20 µg/ml of AAL, conA, or WGA (n = 84–131 trajectories per condition; D). The diffusion coefficients in fixed cells (shown in D) were obtained from an independent experiment (n = 49 trajectories). Pairwise comparisons of the distributions show the following statistically significant differences: DMM vs. control (p < 0.003), AAL, conA, WGA vs. control (p < 10^{-23}), AAL, conA, WGA vs. fixed (p < 10^{-15}). The largest p-value obtained in Kolmogorov-Smirnov test and Mann-Whitney-Wilcoxon test is stated.
c.1090C>T (p.R364X) in ALG8. This patient was born at the 29th week of gestation complicated by oligohydramnios. Although the early postnatal adaptation was uneventful, generalized oedema, multifocal myoclonic seizures, and bleeding due to combined coagulopathy were present from the first day. Diarrhoea progressing to protein-losing enteropathy with ascites and pericardial effusion developed in the third week of life. Pharmacoresistant seizures and cortical, cerebellar and optic nerve atrophy indicated neurological involvement. The patient died at the age of 2 months owing to the progressive general oedema, bleeding and cardio-respiratory insufficiency (Vesela et al., 2009). Indeed, the altered function of the glycosylation machinery observed in patients with a CDG syndrome could result in altered surface and/or synaptic delivery of NMDARs, as many of these patients have impaired brain function (Freeze, 2006; Freeze et al., 2012; Moremen et al., 2012). Unfortunately, the availability of suitable human brain samples from patients with these relatively rare diseases is limited; however, the availability of new techniques for converting human fibroblasts into neuronal cells (Vierbuchen et al., 2010) may provide new opportunities for studying the consequences of impaired glycosylation machinery on the function of NMDARs, possibly leading to the identification of new therapeutic targets for these patients.

AUTHOR CONTRIBUTIONS
MH, KS and YHS designed the study. KS, SL, KL, MK and HH performed the experiments. KS, KL, MK, SL and MZ analyzed the data. YHS and MH wrote the article.

REFERENCES
Chazot, P. L., Cik, M., and Stephenson, F. A. (1995). An investigation into the role of N-glycosylation in the functional expression of a recombinant heteromeric NMDA receptor. Mol. Membr. Biol. 12, 331–337. doi: 10.3109/09687689509072435
Chowdhury, D., Marco, S., Brooks, I. M., Zandueta, A., Rao, Y., Haucke, V., et al. (2013). Tyrosine phosphorylation regulates the endothyrosin and surface expression of GluN3A-containing NMDA receptors. J. Neurosci. 33, 4141–4164. doi: 10.1523/JNEUROSCI.2721-12.2013
Clark, R. A., Gurd, J. W., Bissoon, N., Tricaud, N., Molnar, E., Zamze, S. E., et al. (1998). Identification of lectin-purified neural glycoproteins, GPS 180, 116, and 110, with NMDA and AMPA receptor subunits: conservation of glycosylation at the synapse. J. Neurochem. 70, 2594–2605. doi: 10.1046/j.1471-4159.1998.70062594.x
Coleman, S. K., Moykkynen, T., Cai, C. L., von Ossowski, L., Kuismanen, E., Korpi, E. R., et al. (2006). Isoform-specific early trafficking of AMPA receptor flip and flop variants. J. Neurosci. 26, 11220–11229. doi: 10.1523/neurosci.3201-06.2006
Copits, B. A., Vernon, C. G., Sakai, R., and Swanson, G. T. (2014). Modulation of ionotropic glutamate receptor function by vertebrate galectins. J. Physiol. 592, 2079–2096. doi: 10.1113/jphysiol.2013.269957
Cross, A., Delafosse, L., Gaudry, J. P., Arod, C., Glez, L., Losberger, C., et al. (2012). Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. J. Biotechnol. 161, 336–348. doi: 10.1016/j.jbiotec.2012.06.038
Cummings, R. D., Liu, F. T., and Vasta, G. R. (2017). “Galectins,” in Essentials of Glycobiology [Internet], eds A. Varki, R. D. Cummings, J. D. Esko, P. Stanley, G. W. Hart, M. Aebi, A. G. Darvill, T. Kinoshita, N. H. Packer, J. H. Prestegard, R. L. Schnaar and P. H. Seeberger, 3rd Edn (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press), 2015–2017.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnmol.2018.00188/full#supplementary-material

ACKNOWLEDGMENTS
We thank Ivan Novotny, Michaela Efenberkova and Anna Malinova from the Light Microscopy Core Facility (IMG CAS) for excellent help with the confocal microscopy and for establishing the QD tracking method, and we thank Magda Kuntosova and Nina Ondruskova for preparing the mammalian cell lines.

FUNDING
This work was supported by a project from the Czech Science Foundation (Grantová Agentura České Republiky; 18-04329S) and the Grant Agency of Charles University (Grantová Agentura, Univerzita Karlova; 1520-243-227 060; KS). We acknowledge the Light Microscopy Core Facility, IMG CAS, Prague, Czechia, supported by MEYS (LM2015062), OPKK (CZ.2.16/3.1.00/21547) and NPU I (LO1419). HH was supported by Agentura Pro Zdravotnický Výzkum České Republiky (AZV) 16-31932A from the Ministry of Health of the Czechia, MZ by a project from the Czech Science Foundation 14-16755S. SL and YHS were supported by the National Research Foundation of Korea grants (NRF-2016R1D1A1B03930951, NRF-2017M3C7A1029611) and the Brain Korea 21 PLUS program.
Gregar, I. H., Khatri, L., Kong, X., and Zif, E. B. (2003). AMPA receptor tetramerization is mediated by Q/R editing. 
Neuron 40, 763–774. doi: 10.1016/S0896-6273(03)00668-8

Gross, V., Tran-Thi, T. A., Schwarz, R. T., Elbein, A. D., Decker, K., and Heinrich, P. C. (1986). Different effects of the glucosidase inhibitors 1-deoxynojirimycin, N-methyl-1-deoxynojirimycin and castanospermine on the glycosylation of rat α1-proteinase inhibitor and α1-antitrypsin.
Biochem. J. 236, 853–860. doi: 10.1042/bj236853

Haeuptle, M. A., and Hennet, T. (2009). Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides.
Hum. Mutat. 30, 1628–1641. doi: 10.1002/humu.21126

Hanus, C., Geptin, T., Hrusak, G., Garg, S., Alvarez-Castelao, B., Sambandam, S., et al. (2016). Unconventional secretory processing diversifies neuronal ion channel properties.
Elife 5:e20609. doi: 10.7554/elife.20609

Herrenman, A., Van Gassen, G., Bentahir, M., Nyabi, O., Craessaerts, K., Mueller, U., et al. (2003). γ-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation.
J. Cell Sci. 116, 1127–1136. doi: 10.1242/jcs.00292

Hock, M., Wiegler, K., Rasler, E., Kiechl-Kohlendorfer, U., Scholl-Burg, S., Fauth, C., et al. (2015). ALG8-CDG: novel patients and review of the literature.
Orphanet J. Rare Dis. 10:73. doi: 10.1186/s13023-015-0289-7

Honzik, T., Ondruskova, N., Tesarova, M., Vesela, K., Magner, M., Hennet, T., et al. (2013). Next generation sequencing in diagnostics of two Czech CDGix patients: case reports of patient diagnosed with DPATG1-CDG and SRDSAC-CDG.
J. Inherit. Metab. Dis. 36, 5234–5234. doi: 10.1007/s10545–013–9633-z

Horak, M., Petralia, R. S., Kaniakova, M., and Sans, N. (2014). ER to synapse trafficking of NMDA receptors.
Front. Cell. Neurosci. 8:394. doi: 10.3389/fncel.2014.00394

Huh, K. H., and Wenthold, R. J. (1999). Turnover analysis of glutamate receptors in cultured hippocampal neurons.
J. Neurochem. 70, 2215–2225. doi: 10.1002/jnc.14573-04.2005

Medzihradsky, K. F., Kaasik, K., and Chalkley, R. J. (2015). Tissue-specific glycosylation at the glycopeptide level.
Mol. Cell. Proteomics 14, 2103–2110. doi: 10.1074/mcp.m115.050393

Mikasova, L., Xiong, H., Kerkhofs, A., Bouchet, D., Krugers, H. J., and Groc, L. (2017). Stress hormone rapidly tunes synaptic NMDA receptor through membrane dynamics and mineralocorticoid signalling.
Sci. Rep. 7:8053. doi: 10.1038/s41598–017-06895–3

Mikhaylova, M., Sera, B., Koller, O., Frischknecht, R., and Kreutz, M. R. (2016). A dendritic golgi satellite between ERGIC and retromer.
Cell Rep. 14, 189–199. doi: 10.1016/j.celrep.2015.12.024

Moremen, K. W., Tierney, M., and Nairn, A. V. (2012). Vertebrate protein glycosylation: diversity, synthesis and function.
Nat. Rev. Mol. Cell Biol. 13, 448–462. doi: 10.1038/nrm3383

Ondruskova, N., Honzik, T., Vondrackova, A., Tesarova, M., Zeman, J., and Hansikova, H. (2014). Glycogen storage disease-like phenotype with central nervous system involvement in a PGM1-CDG patient.
Neuro Endocrinol. Lett. 35, 137–141.

Pachernegg, S., Strutz-Seebohm, N., and Hollmann, M. (2012). GluN3 subunit-containing NMDA receptors: not just one-trick ponies.
Trends Neurosci. 35, 240–249. doi: 10.1016/j.tins.2011.11.010

Pérez-Otaño, I., Luján, R., Tavalin, S. J., Plomann, M., Modregger, J., Liu, X. B., et al. (2006). Endocytosis and synaptic removal of NR3A-containing NMDA receptors by PACSIN1/syndapin I.
Nat. Neurosci. 9, 611–621. doi: 10.1038/nn1680

Pérez-Otaño, I., Schulteis, C., T, Contractor, A., Lipton, S. A., Trimmer, J. S., Sucher, N. I., et al. (2001). Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors.
J. Neurosci. 21, 1228–1237. doi: 10.1523/JNEUROSCI.21-04-01228.2001

Przyborski, K., Pu, Z., Losi, G., Hawkins, L. M., Luo, J., Chang, K., et al. (2002). Relationship between availability of NMDA receptor subunits and their expression at the synapse.
J. Neurosci. 22, 8902–8910. doi: 10.1523/JNEUROSCI.22-20-08902.2002

Qu, S., Zhang, X. M., Cao, J. Y., Yang, W., Yan, Y. G., Shan, L., et al. (2009). An endoplasmic reticulum retention signal located in the extracellular amino-terminal domain of the NR2A subunit of N-Methyl-D-aspartate receptors.
J. Biol. Chem. 284, 20285–20298. doi: 10.1074/jbc.m109.049460

Sanz-Clemente, A., Nicol, R. A., and Roche, K. W. (2012). Diversity in NMDA receptor composition: many regulators, many consequences.
Neuroscientist 19, 62–75. doi: 10.1177/1073858411435129

Salzbrunner, I. F., and Koumoutsakos, P. (2005). Feature point tracking and trajectory analysis for video imaging in cell biology.
J. Struct. Biol. 151, 182–195. doi: 10.1016/j.jsb.2005.06.002

Smothers, C. T., and Woodward, J. J. (2009). Expression of glycine-activated diheteromeric NR1/NR3 receptors in human embryonic kidney 293 cells Is NR1 splice variant-dependent.
J. Pharmacol. Exp. Ther. 331, 975–984. doi: 10.1124/jpet.108.158493

Stanley, S., Toacco, G., Wagle, N., and Baudry, M. (1998). High- and low-affinity α1[H3]Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) binding sites represent immature and mature forms of AMPA receptors and are composed of differentially glycosylated subunits.
J. Neurochem. 70, 2434–2445. doi: 10.1523/JNEUROSCI.4573-98.1998

Takahashi, T., Sugiyama, S., and Yosida, H. (1994). Update on defects affecting the biosynthesis of dolichol-linked oligosaccharides.
Mol. Cell. Proteomics 3, 21, 8053. doi: 10.1074/mcp.M10053

Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., et al. (2010). Glutamate receptor ion channels: structure,
regulation, and function. *Pharmacol. Rev.* 62, 405–496. doi: 10.1124/pr.109.002451

Triller, A., and Choquet, D. (2008). New concepts in synaptic biology derived from single-molecule imaging. *Neuron* 59, 359–374. doi: 10.1016/j.neuron.2008.06.022

Tucholski, J., Simmons, M. S., Pinner, A. L., Haroutunian, V., McCullumsmith, R. E., and Meador-Woodruff, J. H. (2013). Abnormal N-linked glycosylation of cortical AMPA receptor subunits in schizophrenia. *Schizophr. Res.* 146, 177–183. doi: 10.1016/j.schres.2013.01.031

Vagin, O., Kraut, J. A., and Sachs, G. (2009). Role of N-glycosylation in trafficking of apical membrane proteins in epithelia. *Am. J. Physiol. Renal Physiol.* 296, F459–F469. doi: 10.1152/ajprenal.90340.2008

Varki, A., Cummings, R. D., and Esko, J. D. (2009). Essentials of Glycobiology. 2nd Edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.

Vesela, K., Honzik, T., Hansikova, H., Hacuptle, M. A., Semberova, J., Stranak, Z., et al. (2009). A new case of ALG8 deficiency (CDG Ih). *J. Inherit. Metab. Dis.* 32, 259–264. doi: 10.1007/s10545-009-1203-z

Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Südhof, T. C., and Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* 463, 1035–1041. doi: 10.1038/nature08797

Wong, H. K., Liu, X. B., Matos, M. F., Chan, S. F., Pérez-Otaño, I., Boysen, M., et al. (2002). Temporal and regional expression of NMDA receptor subunit NR3A in the mammalian brain. *J. Comp. Neurol.* 450, 303–317. doi: 10.1002/cne.10314

Yang, E. H., Rode, J., Howlader, M. A., Eckermann, M., Santos, J. T., Hernandez Armada, D., et al. (2017). Galectin-3 alters the lateral mobility and clustering of β1-integrin receptors. *PLoS One* 12:e0184378. doi: 10.1371/journal.pone.0184378

Yavin, E., Richter-Landsberg, C., Duksin, D., and Yavin, Z. (1984). Tunicamycin blocks neuritogenesis and glucosamine labeling of gangliosides in developing cerebral neuron cultures. *Proc. Natl. Acad. Sci. U S A* 81, 5638–5642. doi: 10.1073/pnas.81.18.5638

Yuan, T., and Bellone, C. (2013). Glutamatergic receptors at developing synapses: the role of GluN3A-containing NMDA receptors and GluA2-lacking AMPA receptors. *Eur. J. Pharmacol.* 719, 107–111. doi: 10.1016/j.ejphar.2013.04.056

Zagyansky, Y., and Edidin, M. (1976). Lateral diffusion of concanavalin A receptors in the plasma membrane of mouse fibroblasts. *Biochim. Biophys. Acta* 433, 209–214. doi: 10.1016/0005-2736(76)90188-7

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Skrenkova, Lee, Lichnerova, Kaniakova, Hansikova, Zapotocky, Suh and Horak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.